Earlier studies from our lab revealed, however, that the IL-33-ST2 alarmin pathway contributes essentially to the effectiveness of artARENA-vectored cancer immunotherapy,29 and the vector’s ability to trigger this pathway correlates with its spread into IL-33-expressing splenic stromal cells. The gene discussed is IL33; the disease is cancer.